No connection

Search Results

PETS

BEARISH
$2.34 Live
PetMed Express, Inc. · NASDAQ
Target $2.75 (+17.5%)
$1.57 52W Range $4.32

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$50.08M
P/E
N/A
ROE
-100.6%
Profit margin
-34.7%
Debt/Equity
0.02
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
PETS exhibits a stable Piotroski F-Score of 5/9, but this is overshadowed by catastrophic fundamental decay. The company is experiencing a severe collapse in profitability with an ROE of -100.61% and accelerating revenue declines (-21.7% YoY, -29.95% Q/Q). Despite a very low Debt/Equity ratio, the current ratio of 0.89 indicates immediate liquidity risks, while a 0/4 earnings beat record over the last year suggests a complete loss of operational control.

Key Strengths

Very low Debt/Equity ratio (0.02)
Low Price/Sales ratio (0.27) suggesting deep value if a turnaround occurs
Piotroski F-Score of 5/9 indicates baseline financial stability compared to total collapse
Positive Gross Margin (27.53%) showing the core product still has value
Low overall leverage

Key Risks

Severe revenue contraction (-21.7% YoY)
Extreme earnings volatility and massive misses (Avg surprise -1371.82%)
Liquidity risk with a Current Ratio below 1.0 (0.89) and Quick Ratio of 0.52
Negative profit margins (-34.70%) and operating margins (-25.73%)
Long-term price destruction (-91.2% over 5 years)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
18
Weak
Value
30
Future
5
Past
10
Health
45
Dividend
0
AI Verdict
Value Trap / High Risk
Key drivers: Accelerating revenue decline, Catastrophic ROE, Consistent earnings misses, Bearish technical trend
Confidence
90%
Value
30/100

Trades at a low multiple of sales, but earnings are non-existent.

Positives
  • Low P/S ratio (0.27)
  • Low P/B ratio (1.53)
Watchpoints
  • Negative Forward P/E
  • No Graham Number due to negative earnings
Future
5/100

Growth metrics are in a state of freefall.

Positives
No standout positives identified.
Watchpoints
  • YoY Revenue Growth -21.70%
  • Q/Q Revenue Growth -29.95%
  • YoY EPS Growth -1566.7%
Past
10/100

Long-term historical performance is overwhelmingly negative.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change -91.2%
  • 3Y Change -84.4%
  • Consistent failure to meet analyst estimates
Health
45/100

Low debt is the only saving grace, but liquidity is tightening.

Positives
  • Low Debt/Equity (0.02)
  • Piotroski F-Score 5/9
Watchpoints
  • Current Ratio < 1.0
  • Quick Ratio 0.52
Dividend
0/100

Non-dividend paying stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No history of payouts

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.34
Analyst Target
$2.75
Upside/Downside
+17.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PETS and closest competitors.

Updated 2026-04-16
PET
PetMed Express, Inc.
Primary
5Y
-91.2%
3Y
-84.4%
1Y
-23.0%
6M
-7.9%
1M
-8.2%
1W
+1.3%
HYF
MindWalk Holdings Corp.
Peer
5Y
-91.3%
3Y
-62.5%
1Y
+166.8%
6M
-40.9%
1M
-16.4%
1W
-6.1%
NTR
Nutriband Inc.
Peer
5Y
-28.9%
3Y
+17.2%
1Y
-16.9%
6M
-45.8%
1M
+7.4%
1W
+4.1%
POC
Precision Optics Corporation, Inc.
Peer
5Y
-7.8%
3Y
-29.0%
1Y
+17.5%
6M
+13.0%
1M
+13.2%
1W
+17.8%
ELU
Elutia Inc.
Peer
5Y
-91.4%
3Y
-20.8%
1Y
-53.7%
6M
+28.2%
1M
-2.6%
1W
+4.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-78.0
PEG Ratio
2.32
P/B Ratio
1.53
P/S Ratio
0.27
EV/Revenue
0.13
EV/EBITDA
-0.82
Market Cap
$50.08M

Profitability

Profit margins and return metrics

Profit Margin -34.7%
Operating Margin -25.73%
Gross Margin 27.53%
ROE -100.61%
ROA -20.32%

Growth

Revenue and earnings growth rates

Revenue Growth -21.7%
Earnings Growth N/A
Q/Q Revenue Growth -29.95%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.02
Low debt
Current Ratio
0.89
Weak
Quick Ratio
0.52
Poor
Cash/Share
$1.26

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
23.3%
Op. Margin
-25.7%
Net Margin
-26.0%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
1.68x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-06-10
$N/A
2026-02-05
$-0.5
-733.3% surprise
2025-12-19
$-0.41
-1125.0% surprise
2025-12-19
$-1.65
-2257.1% surprise

Healthcare Sector Comparison

Comparing PETS against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-100.61%
This Stock
vs
-101.52%
Sector Avg
-0.9% (Below Avg)
Profit Margin
-34.7%
This Stock
vs
-12.47%
Sector Avg
+178.3% (Superior)
Debt to Equity
0.02
This Stock
vs
3.4
Sector Avg
-99.4% (Less Debt)
Revenue Growth
-21.7%
This Stock
vs
124.21%
Sector Avg
-117.5% (Slower)
Current Ratio
0.89
This Stock
vs
4.56
Sector Avg
-80.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

MENNEN JUSTIN L.
Director
Stock Award
2025-10-30
33,846 shares
LACAMP JAMES
Director
Stock Award
2025-10-30
34,866 shares
SOLIVAN LEAH A.
Director
Stock Award
2025-10-30
33,846 shares
BATUSHANSKY PETER
Director
Stock Award
2025-10-30
33,846 shares
KRULIK DOUGLAS
Chief Financial Officer
Stock Award
2025-10-30
20,000 shares
FULGONI GIAN M
Director
Stock Award
2025-10-30
33,846 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-Q
10-Q
2026-02-05

PETS's 10-Q filing dated February 5, 2026, does not provide specific financial highlights in the provided excerpt. However, the company identifies a key risk regarding unsolicited acquisition proposals and proxy contests, which could result in substantial costs, business disruption, and stock price volatility.

8-K
8-K
2026-01-23

PETS filed an 8-K on January 23, 2026, likely announcing its year-end financial results.

8-K/A
8-K/A
2025-12-29

PETS filed an amendment to a previously submitted current report on December 29, 2025.

10-Q
10-Q
2025-12-19

The provided filing for PETS does not include specific financial highlights but emphasizes risks related to unsolicited acquisition proposals and proxy contests. Such activities could result in substantial costs, divert management's attention, and cause significant fluctuations in the company's stock price.

10-Q
10-Q
2025-12-19

The provided filing for PETS does not include specific financial highlights but emphasizes risks related to unsolicited acquisition proposals and proxy contests. Such activities could result in substantial costs, divert management's attention, and cause significant fluctuations in the company's stock price.

DEF 14A
DEF 14A
2025-12-10

PETS filed a definitive proxy statement (DEF 14A) on December 10, 2025, providing shareholders with necessary information and materials for an upcoming vote.

8-K
8-K
2025-12-09
8-K
8-K
2025-11-26
8-K
8-K
2025-11-13

PETS likely reported its third-quarter financial results in this 8-K filing dated November 13, 2025.

8-K
8-K
2025-10-21

PETS filed an 8-K on October 21, 2025, likely to report its third-quarter financial results.

10-K
10-K
2025-10-14
8-K
8-K
2025-10-14
8-K
8-K
2025-10-07
8-K
8-K
2025-09-12
8-K
8-K
2025-08-25
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning PETS from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile